We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

An Epigenetic Change Causes the Block of Antitumor Genes

Read time: Less than a minute

This balance is disrupted in tumor cells. There are many causes, for example, the existence of mutations, but also the acquisition of a chemical signal, methylation, which blocks the activity of genes that stop cancer growing. It is unknown, however, what happens in the cells after they have acquired this epigenetic alteration.

Researchers of the IDIBELL, led by Manel Esteller, director of the Epigenetics and Cancer Biology Program, ICREA researcher and professor at the University of Barcelona, describe in the online edition of the journal Oncogene how this methylation triggers a dimensional change in the nucleus cell to form spherical structures called nucleosomes that block the function of antitumor genes.

Researchers observed that genes that protect from cancer as the vitamin A receptor alter its activity in colon cancer cells by the presence of spherical structures formed by DNA (in this case expression regulatory regions of genes) and proteins called histones.

"We have observed," said the researcher Manel Esteller, "that epigenetic drugs, capable of demethylating DNA, approved for patients with a subtype of leukemia, are also able to eliminate these 'balls' of antitumor genes so that they can express again, and recover their function."

“This study”, explained Esteller, “also served to discover new genes, inhibitors of cancer.”

The discovery increases the molecular understanding of the causes of cancer and as to the clinical application of the discovery; Esteller explained that "there is currently a wide range of drugs in preclinical development capable of ejecting nucleosomes of aberrant places of the genome".

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.